How can I make an appointment to receive the bivalent mRNA vaccine in Hong Kong at my own expense?
Read Time:1 Minute, 42 Second
On December 27, Fosun Health announced that its online platform has officially opened the registration of intent to receive Fubatai bivalent vaccine in Hong Kong.
From now on, users can log on to Fosun Health’s platform or WeChat app, find the “New Crown Vaccine” portal on the homepage, and register their intention to receive Fubatai bivalent vaccine in Hong Kong, and after a successful appointment, they can go to Hong Kong to receive Fubatai bivalent vaccine at their own cost after customs clearance between the two places officially resumes.
On March 16, 2020, Fosun Pharma and BioNTech (Germany) announced a strategic partnership for mRNA vaccine development, whereby Fosun Pharma is authorized by BioNTech to exclusively develop and commercialize new crown vaccines based on its proprietary mRNA technology platform in Mainland China, Hong Kong, Macau and Taiwan.
In December 2022, both the mRNA neo-crown vaccine, fubotide BNT162b2, and the fubotide bivalent vaccine were officially registered as China Hong Kong drugs/products (biologics). Following this registration in Hong Kong, China, people who wish to receive the vaccine can do so at medical institutions or clinics in Hong Kong, China, with a prescription from their local doctor.
Fupirtide bivalent vaccine is an mRNA vaccine based on the Omicron variant and is an iteration and complement to the already marketed Fupirtide BNT162b2. Each dose of Fupirtide bivalent vaccine contains 15 micrograms of mRNA encoding the spiked protein of the original strain and 15 micrograms of mRNA encoding the spiked protein of the Omicron BA.4/BA.5 variant.
It is worth mentioning that on the evening of December 22, Fosun Pharma (600196.SH, 02196.HK) and BioNTech SE (“BioNTech”) jointly announced that approximately 11,500 doses of Fubitai mRNA New Crown vaccine, including the vaccine for Omicron BA.4/BA.5 variant, had arrived in Beijing, China on December 21, 2022. With the arrival of these two vaccines in Beijing, it is expected that Fubetide Neocrown vaccination will be offered to German citizens residing in China in Beijing, Shanghai, Guangzhou, Shenyang and Chengdu.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
Average Rating